Potential COVID-19 papain-like protease PLpro inhibitors : repurposing FDA-approved drugs
© 2020 Kouznetsova et al..
Using the crystal structure of SARS-CoV-2 papain-like protease (PLpro) as a template, we developed a pharmacophore model of functional centers of the PLpro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PLpro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed by docking of possible conformers to the binding pocket of PLpro. Docking of random compounds to the binding pocket of protease was also done for comparison. Free energies of the docking interaction for the selected compounds were lower than for random compounds. The drug list obtained includes inhibitors of HIV, hepatitis C, and cytomegalovirus (CMV), as well as a set of drugs that have demonstrated some activity in MERS, SARS-CoV, and SARS-CoV-2 therapy. We recommend testing of the selected compounds for treatment of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
PeerJ - 8(2020) vom: 01., Seite e9965 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kouznetsova, Valentina L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7717/peerj.9965 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315702621 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315702621 | ||
| 003 | DE-627 | ||
| 005 | 20240330232948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7717/peerj.9965 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM315702621 | ||
| 035 | |a (NLM)32999768 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kouznetsova, Valentina L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential COVID-19 papain-like protease PLpro inhibitors |b repurposing FDA-approved drugs |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 Kouznetsova et al. | ||
| 520 | |a Using the crystal structure of SARS-CoV-2 papain-like protease (PLpro) as a template, we developed a pharmacophore model of functional centers of the PLpro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PLpro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed by docking of possible conformers to the binding pocket of PLpro. Docking of random compounds to the binding pocket of protease was also done for comparison. Free energies of the docking interaction for the selected compounds were lower than for random compounds. The drug list obtained includes inhibitors of HIV, hepatitis C, and cytomegalovirus (CMV), as well as a set of drugs that have demonstrated some activity in MERS, SARS-CoV, and SARS-CoV-2 therapy. We recommend testing of the selected compounds for treatment of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Computational drug design | |
| 650 | 4 | |a Drugs repurposing | |
| 650 | 4 | |a Papain-like protease | |
| 700 | 1 | |a Zhang, Aidan |e verfasserin |4 aut | |
| 700 | 1 | |a Tatineni, Mahidhar |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Tsigelny, Igor F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PeerJ |d 2013 |g 8(2020) vom: 01., Seite e9965 |w (DE-627)NLM227171578 |x 2167-8359 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g day:01 |g pages:e9965 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7717/peerj.9965 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |b 01 |h e9965 | ||